ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2165

Utility of Vectra-DA™ On Assessment of Rheumatoid Arthritis Disease Activity and Golimumab Response:  Results of a Pilot Study From a Phase 3 Trial in Patients with Active Rheumatoid Arthritis Despite Methotrexate Therapy

Sarah Lamberth, Yauheniya Cherkas, Carrie Brodmerkel and Mark Curran, Janssen Research & Development, LLC., Spring House, PA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis Treatment - Small Molecules, Biologics and Gene Therapy

Session Type: Abstract Submissions (ACR)

Background/Purpose: Currently, disease activity in Rheumatoid Arthritis (RA) is measured using scoring systems that rely primarily on a collection of subjective measures from patients and clinicians.  To improve care and treatment for RA patients, objective measurements of disease activity and response to treatment are desirable.  Using a small cohort derived from an ongoing study of intravenously administered golimumab (GO-FURTHER), we evaluated the performance of Vectra-DA™ (Crescendo Biosciences), a multi-biomarker serum-based test designed to measure RA disease activity through correlation with DAS28-CRP and sensitive to anti-TNF therapy.1This analysis examines if Vectra-DA™correlates with disease activity and golimumab response in a clinical trial setting.

Methods: 137 serum samples collected in a Phase III study of intravenously administered golimumab in patients with active RA despite methotrexate (MTX) therapy was analyzed using Vectra-DA™ (Crescendo Bioscience©; San Francisco, CA, USA). Samples were collected at weeks 0, 2, 4, and 14 from patients treated with IV placebo + MTX (PBO; n= 42) or IV golimumab 2mg/kg + MTX (GLM; n=95) who received study medications at Weeks 0, 4, and every 8 weeks thereafter.  Healthy control serum samples (n=21) were obtained from Bioreclamation (Hicksville, NY). 

Results: A subset of subjects was chosen for analysis with Vectra-DA™ from the GO-FURTHER study.  The subset had an ACR50 response to golimumab of 35.8% (PBO 7.1%) at week 14 and 48.4% (PBO 16.7%) at week 24.  Correlation of Vectra-DA™ and DAS28-CRP scores was r=0.51 (95% CI=0.45-0.57) using all four timepoints tested.  Study subjects had statistically higher mean Vectra-DA™ scores (64.2 at wk 0; 45.5 at wk 2; 50.2 at wk4; 44.9 at wk14) compared to healthy controls (35.2).   At baseline, there were no significant differences in GLM and PBO-treated subjects by Vectra-DA™ or DAS28-CRP scores.  As early as week 2, GLM-treated subjects had a significant drop in Vectra-DA™ score of
D= -18.7 (p=<2.2X10-16).  The decrease in Vectra-DA™ score was maintained through week 14, whereas PBO-treated subjects did not have a significant change in Vectra-DA™ scores from baseline to weeks 2, 4 and 14.  Vectra-DA™ scores were statistically different between GLM-treated subjects who achieved an ACR50 response at week 14 versus non-responders at weeks 0 (p=0.024), 4 (p=0.013), and 14 (p=0.009).  Vectra-DA™ scores were not statistically different between GLM-treated subjects who achieved an ACR50 response at week 24 versus non-responders at all timepoints tested, though a trend was seen at week 14 (p= 0.054).

Conclusion: Vectra-DA™ offers a molecular measurement of RA disease activity that can discriminate between normal and RA subjects, and also PBO and GLM-treated subjects as early as week 2 post-treatment.  GLM treated week 14 responders had significantly lower Vectra-DA™ scores compared with non-responders.  The Vectra-DA™ score reflects a patient’s disease activity before and after the treatment with intravenous golimumab.

1Weinblatt ME, Shadick NA, Manning W, et al. Use of a Multi-Biomarker Score for Rheumatoid Arthritis Disease Activity (Vectra™ DA) to Assess Response to Therapy. (Poster Session I: May 26, 2011, 11:45 BST). EULAR Congress 2011.


Disclosure:

S. Lamberth,

Janssen Research and Development, LLC,

3;

Y. Cherkas,

Janssen Research and Development, LLC,

3;

C. Brodmerkel,

Janssen Research and Development, LLC,

3;

M. Curran,

Janssen Research and Development, LLC,

3.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-vectra-da-on-assessment-of-rheumatoid-arthritis-disease-activity-and-golimumab-response-results-of-a-pilot-study-from-a-phase-3-trial-in-patients-with-active-rheumatoid-arth/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified ­­­presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2023 American College of Rheumatology